iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Sun Pharma Q3 net up 11.14% yoy at Rs2,059cr on 8% growth in EBITDA and EBTIDA margins at 26.1%

1 Feb 2022 , 09:01 AM

Sun Pharma
Sun Pharma Ltd reported 11.61% yoy growth in total sales revenues for the Dec-21 quarter on consolidated basis at Rs9,863cr. On a sequential basis, the revenues were up by 2.46%.

During the December 2021 quarter, the India formulation sales grew by 15% yoy, US formulations grew 6% at $397 million while the emerging markets formulations business grew by 17% yoy. Even the rest of the world saw a marginal 3% growth in top line on a yoy basis.

Over a 9 month period, the India business was the fastest growing at 26% as India traction built up substantially in the last couple of years. The board of Sun Pharma has also declared an interim dividend of Rs.7 per share.

For the Dec-21 quarter, the operating profits were up on a yoy basis by 9.52% at Rs2,053cr. During the quarter, there was solid traction in EBITDA growth by 8% at Rs2,558cr while the EBITDA margins came in at a healthy 26.1% in the quarter.

Sun Pharma reported sharp growth in the India business where it dominates with nearly 8.2% market share. In the US, Taro reported lower net profits by 20% yoy on price pressure in the generics business.

Operating margins fell marginally from 21.21% in Dec-20 quarter to 20.81% in the Dec-21 quarter. Operating margins were lower on a sequential basis by 21 bps.

Net Profit after tax (PAT) for the Dec-21 quarter was up 11.14% yoy at Rs2,059cr on the back of the robust operating performance getting transmitted to the bottom line. R&D expenses at Rs547cr were robust at well above 5% of sales revenues. In the first nine months of the fiscal till date,

Sun Pharma has repaid $254 million of debt, reducing its financial risk further with internal resources. The API business continues to be under pressure, but that has been the trend globally.

PAT margins fell marginally from 20.96% in the Dec-20 quarter to 20.87% in the Dec-21 quarter. The PAT margins were also lower on a sequential basis.

Financial highlights for Dec-21 compared yoy and sequentially

Sun Pharma
Rs in Crore Dec-21 Dec-20 YOY Sep-21 QOQ
Total Income (Rs cr) ₹ 9,863.06 ₹ 8,836.78 11.61% ₹ 9,625.93 2.46%
EBITDA (Rs cr) ₹ 2,052.65 ₹ 1,874.20 9.52% ₹ 2,099.57 -2.23%
Net Profit (Rs cr) ₹ 2,058.80 ₹ 1,852.48 11.14% ₹ 2,047.01 0.58%
Diluted EPS (Rs) ₹ 8.60 ₹ 7.70 ₹ 8.50
EBITDA Margin 20.81% 21.21% 21.81%
Net Margins 20.87% 20.96% 21.27%

Related Tags

  • Pharma Sector
  • Q3 FY2022 results of Sun Pharma
  • Sun Pharma management
  • Sun Pharma news
  • Sun Pharma Q3
  • Sun Pharma Q3FY22 PAT
  • Sun Pharma Q3FY22 Pharma Business
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.